ESRF Lightsource Helps Tailoring new Treatments Against Asthma
News Aug 10, 2007
Asthma affects 300 million people worldwide and, according to World Health Organization, it killed 255 000 people in 2005. Asthma attacks are caused by an acute inflammatory reaction in the airways, a reaction that is largely due to actions of LTC4 synthase (an enzyme which catalyzes a synthesis process). For this reason asthma medicines often aim to block the downstream effects of LTC4 synthase.
However, there is a need for new pharmaceutical alternatives, since not all patients respond to the existing medicines. Thanks to the research partly carried out at the European Synchrotron Radiation Facility (ESRF), it is now possible to tailor new molecules that can block the LTC4 synthase. “I believe this breakthrough will speed up drug discovery against this disease”, explains Andrew McCarthy, one of the researchers in the team.
Scientists from the Karolinska Institute and the University of Stockholm in Sweden, together with colleagues from the European Molecular Laboratory in France have solved the three dimensional structure of the LTC4 synthase at 2.0 Angstrom resolution.
The protein has three identical subunits, each consisting of four helical structures that span the membrane. The structure finally allows the exact position and characteristics of the active sites, where activating or blocking molecules can bind, to be identified.
The study of this protein at the ESRF proved a challenge for the team. The crystallization of membrane proteins is quite a complex process and even more challenging if they are human. So far only three human membrane proteins have been structurally characterized. The team carried out experiments at the ESRF to screen crystals several times before finally being able to determine the 3D structure.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Sciformix Corporation Collaborates with Oracle Health SciencesNews
New collaboration enables faster and more informed drug safety decisions.READ MORE